0 5 ICSAT ICSAT NNP 6 20 overexpression overexpression NN 21 23 is be VBZ 24 27 not not RB 28 38 sufficient sufficient JJ 39 41 to to TO 42 47 cause cause VB 48 53 adult adult JJ 54 60 T-cell t-cell NN 61 69 leukemia leukemia NN 70 72 or or CC 73 81 multiple multiple JJ 82 89 myeloma myeloma NN 89 90 . . . 92 97 ICSAT ICSAT NNP 98 99 ( ( ( 99 109 Interferon Interferon NNP 110 119 Consensus Consensus NNP 120 128 Sequence sequence NN 129 136 binding binding NN 137 144 protein protein NN 145 148 for for IN 149 158 Activated activate VBN 159 160 T t NN 161 166 cells cell NNS 166 167 ) ) ) 168 170 is be VBZ 171 172 a a DT 173 192 lymphocyte-specific lymphocyte-specific JJ 193 199 member member NN 200 202 of of IN 203 206 the the DT 207 217 interferon interferon NN 218 228 regulatory regulatory JJ 229 235 factor factor NN 236 237 ( ( ( 237 240 IRF IRF NNP 240 241 ) ) ) 242 248 family family NN 249 251 of of IN 252 265 transcription transcription NN 266 273 factors factor NNS 273 274 , , , 275 285 originally originally RB 286 296 identified identify VBN 297 304 through through IN 305 317 Southwestern southwestern JJ 318 327 screening screening NN 328 330 of of IN 331 334 the the DT 335 344 ATL(Adult atl(adult JJ 345 351 T-cell T-cell NNP 352 365 leukemia)-16T leukemia)-16t NN 366 376 expression expression NN 377 384 library library NN 384 385 . . . 386 388 In in IN 389 393 this this DT 394 399 study study NN 399 400 , , , 401 403 we we PRP 404 411 created create VBD 412 422 transgenic transgenic JJ 423 427 mice mouse NNS 428 442 overexpressing overexpresse VBG 443 448 ICSAT icsat NN 449 451 in in IN 452 463 lymphocytes lymphocyte NNS 463 464 . . . 465 473 Although although IN 474 485 spontaneous spontaneous JJ 486 499 tumorigenesis tumorigenesis NN 500 503 was be VBD 504 507 not not RB 508 516 observed observe VBN 516 517 , , , 518 522 IL-2 il-2 NN 523 533 production production NN 534 538 with with IN 539 551 Concanavalin Concanavalin NNP 552 553 A a NN 554 565 stimulation stimulation NN 566 569 was be VBD 570 583 significantly significantly RB 584 593 increased increase VBN 594 596 in in IN 597 607 transgenic transgenic JJ 608 612 mice mouse NNS 613 627 overexpressing overexpresse VBG 628 633 ICSAT ICSAT NNP 633 634 . . . 635 640 ICSAT ICSAT NNP 641 655 overexpression overexpression NN 656 658 in in IN 659 670 lymphocytes lymphocyte NNS 671 676 seems seem VBZ 677 689 insufficient insufficient JJ 690 693 for for IN 694 697 the the DT 698 712 leukemogenesis leukemogenesis NN 713 715 of of IN 716 719 ATL ATL NNP 720 722 or or CC 723 731 multiple multiple JJ 732 739 myeloma myeloma NN 740 741 ( ( ( 741 743 MM MM NNP 743 744 ) ) ) 744 745 , , , 746 753 however however RB 753 754 , , , 755 757 it it PRP 758 761 may may MD 762 770 regulate regulate VB 771 772 T t NN 773 777 cell cell NN 778 788 activation activation NN 789 792 and and CC 793 796 its its PRP$ 797 811 overexpression overexpression NN 812 815 may may MD 816 820 lead lead VB 821 823 to to TO 824 838 leukemogenesis leukemogenesis NN 839 842 via via IN 843 854 controlling control VBG 855 859 IL-2 il-2 NN 860 870 production production NN 870 871 . . . 872 881 Copyright Copyright NNP 882 886 1999 1999 CD 887 895 Academic Academic NNP 896 901 Press Press NNP 901 902 . . .